Source: Forbes
Security & Justice
Southern Lebanon Endures Massive Damage: 40,000 Homes Leveled Across 37 Towns
Israeli forces have systematically destroyed entire neighborhoods in southern Lebanon, leveling more than 37 towns and wiping out over 40,000 residential units, according to Lebanon's National News Agency.
Tuesday, November 5, 2024
Gaps in Coastal Radar Enabled Israeli Raid in Batroun, Army Commander Says
Lebanon’s army chief, General Joseph Aoun, detailed to Caretaker Prime Minister Najib Mikati how Israeli forces likely exploited gaps in the country's coastal radar system during the recent raid carried out in Batroun. The briefing comes as Lebanese officials seek answers on how Israel’s elite Shayetet 13 unit carried out the landing undetected.
Monday, November 4, 2024
Opinion
The Emptying of Baalbek Is a Moment to Take Stock
“Large numbers of people continue to flee their homes every day, as Israel’s military operations in Lebanon have been going on unabated.” These disturbing words could be from almost any news report about Israel’s invasion of its northern neighbour over the past month. However, they can be found in a report by the Norwegian Refugee Council’s Internal Displacement Monitoring Centre issued on July 27, 2006.
Saturday, November 2, 2024
A Future Without Hezbollah
At the end of September, when Israel’s campaign to destroy Hezbollah was reaching its height, I met one of the group’s supporters in a seaside café in western Beirut. He was a middle-aged man with a thin white beard and the spent look of someone who had not slept for days. He was an academic of sorts, not a fighter, but his ties to Hezbollah were deep and long-standing.
Thursday, October 31, 2024
Sports
Tottenham Forward Son Heung-min Crowned Asia’s International Player of the Year
Tottenham forward Son Heung-min was crowned as Asia’s International Player of the Year for the fourth time by the Asian Football Confederation at its annual awards ceremony Tuesday.
Wednesday, October 30, 2024
Real Madrid Launch Investigation into Racist Insults After El Clasico Defeat
Real Madrid has launched an investigation into racist insults directed at players during Saturday’s 4-0 home loss to Barcelona in LaLiga, it said on Sunday.
Monday, October 28, 2024
Friday 5 July 2024 18:51:51
Drugs Like Ozempic Could Lower Cancer Risks, Study Suggests
A class of diabetes and weight loss drugs that includes Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro could also help protect against a variety of cancers, according to new research published Friday, adding to mounting evidence the injections offer numerous additional health benefits as pressure builds for insurers and public health providers to cover the popular medication in spite of persistent shortages and cost concerns.
KEY FACTS
Glucagon-like peptide receptor agonists, a class of drugs often known as GLP-1s or GLP-1RAs, were associated with a “significant risk reduction” for 10 different cancers when used to treat type 2 diabetes compared to insulin, according to new research published in JAMA Oncology.
The findings come from an analysis of the electronic health records of 1.7 million U.S. patients over 15 years who were prescribed GLP-1RAs, insulins or metformin for type 2 diabetes — all help control blood sugar — between 2005 to 2018, though it did not specify which drugs were examined.
GLP-1 drugs, which mimic the action of a gut hormone and can help control blood sugar, include popular obesity and diabetes treatments like Ozempic and Wegovy (brand names for semaglutide), Mounjaro and Zepbound (or tirzepatide), Victoza and Saxenda (liraglutide) and Trulicity (dulaglutide).
Semaglutide was only authorized for medical use towards the end of the study timeline and tirzepatide was not approved until much later, though findings for some drugs can give an indication for what might happen with closely related drugs.
All of the 13 cancers studied are considered obesity-associated cancers as excess body fat has been linked to a greater risk of developing them and worse prognosis among patients who do.
GLP-1RAs were linked to a greatly reduced risk of developing esophageal, colorectal, endometrial, gallbladder, kidney, liver, ovarian, and pancreatic cancers, as well as meningioma and multiple myeloma, compared to patients taking insulin.
There was no firm evidence for a lower risk for developing the obesity-associated cancers compared to patients taking metformin for their diabetes, however, though the researchers said there were promising but statistically insignificant indications of a lower risk for gallbladder and colorectal cancer.
SURPRISING FACT
While GLP-1RAs were associated with a decreased risk for most obesity-associated cancers studied compared to other standard diabetes treatments, the researchers said drugs were also associated with a risk of developing some cancers. Compared to patients on metformin, patients taking GLP-1RAs had a higher risk of kidney cancers, the researchers said, though the risk was also lower than patients taking insulin.
There have been no previous reports of kidney cancers associated with using GLP-1s, which are known to have direct effect on kidney function and have been linked to lower rates of kidney disease.
Nevertheless, the researchers said the findings should be followed up for “full evaluation” and suggest the need for continuous monitoring of patients being treated with GLP-1RAs.
There was also no significant reduction in the risk of developing thyroid cancer for patients taking GLP-1RAs compared to insulins, the researchers said.
This finding adds weight to existing research highlighting concerns the drugs are associated with an increased risk of developing thyroid cancer and support warnings on drug packages advising caution among patients with endocrine or thyroid problems.
WHAT WE DON’T KNOW
The study was observational in nature and therefore can only determine relationships, not cause and effect. It’s possible the reduction in risk for obesity-associated cancers comes from the weight loss and diabetes control afforded by such medications, as these are both issues linked to higher risks of cancers, or from some action of the drug itself or another thing entirely.
Given the data available, the researchers said the study doesn’t consider “newer and possibly more effective antidiabetic and weight loss agents,” which could show even more pronounced effects, as well as those with multihormone agonist activities that are increasingly coming to market (tirzepatide, for example, is a multihormone agonist).
